MicroRNAs in Acute Kidney Injury

Kidney Injury in Cardiac Surgery - Expression of microRNAs Clinical Trial

— MIRAKI  

Official title:

MicroRNAs in Acute Kidney Injury (MIRAKI) - a Pilotstudy -

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03089242
• Other study ID #: 2017024132
• Status: Completed
• Start date: September 1, 2017
• Est. completion date: December 31, 2018

Study information

• Verified date: May 2020
• Source: Heinrich-Heine University, Duesseldorf
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Profiling of microRNAs and long noncoding RNAs (lncRNAs) in patients undergoing cardiac surgery. Analysis: Prediction of acute kidney injury by plasma expression profile of microRNAs?

Description:

In this pilot study we will include 150 patients undergoing cardiac surgery in a German university hospital. We will profile microRNA expression in plasma and urine before and at several timepoints after surgery. We will use a preselected panel of microRNAs and lncRNAs for analysis. Goal is to identify microRNAs/lncRNAs that are able to predict the occurence of AKI in these patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: December 31, 2018
• Est. primary completion date: June 30, 2018
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• cardiac surgery

Exclusion Criteria:

• preexisting chronic kidney injury

• inclusion in another study

• pregnancy

• Kidney transplantation in history

• GFR < 30 ml/min (glomerular filtration rate)

• ECLS therapy (extracorporal life support)

Related Conditions & MeSH terms

• Acute Kidney Injury
• Kidney Injury in Cardiac Surgery - Expression of microRNAs
• Wounds and Injuries

Intervention

Other:
• observation of microRNA expression
no intervention

Locations

Country	Name	City	State
Germany	Klinik für Anästhesiologie	Düsseldorf

Sponsors (1)

Lead Sponsor	Collaborator
Heinrich-Heine University, Duesseldorf

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	acute kidney injury	AKI Stadium II or III following cardiac surgery.	1 year